US 10 year yields are near multi month highs as investors respond to inflation concerns and heavy debt issuance. Higher yields can make it harder and more expensive for smaller companies to raise money, which is one reason many penny stocks struggle. The Financially Fit Penny Stocks screener filters for stronger balance sheets and healthier cash profiles. This article highlights three stocks from the screener that aim to balance growth potential with financial discipline.

The stocks covered below are just a small sample of the opportunities that meet these filters, and the full screen surfaced 3,639 more companies with financial profiles and business stories that are not covered in this article. If you want to identify and analyze potential high conviction ideas that fit the same criteria, head straight to the Financially Fit Penny Stocks screener.

Mesoblast (ASX:MSB)

Overview: Mesoblast is a Melbourne based biotech company focused on developing mesenchymal lineage cell therapies such as Remestemcel L and MPC based products for severe inflammatory and cardiovascular conditions, including graft versus host disease, inflammatory bowel disease, chronic heart failure and chronic low back pain. This clinical stage focus on concrete cell therapy assets fits the Financially Fit Penny Stocks theme of earlier stage companies where the main attraction is a solid, development ready pipeline rather than diversified revenue streams.

Operations: Mesoblast currently generates its revenue, around US$65 million, from developing its cell technology platform for future commercialization rather than from a broad product sales base.

Market Cap: A$3.1 billion

Mesoblast gives you exposure to a focused cell therapy platform that already includes an FDA approved product, Ryoncil, and late stage programs in areas like chronic low back pain and heart failure where regulators have granted RMAT designations and pivotal trials are underway. At the same time, the company is still loss making, spends heavily on development and depends on external funding, so outcomes for these trials and reimbursement decisions matter a lot. Recent financing on fixed 8% debt and a cash balance of US$122 million support the push through key milestones. However, execution risk around label expansions, adult indications and large chronic markets remains high, which is one factor that can make Mesoblast an interesting penny stock to research further.

Mesoblast is pushing hard on late stage cell therapies while still relying on external funding and fixed 8% debt. Before you decide how that trade off sits in your portfolio, scan the analysis report for Mesoblast for further detail on the situation.

Build your own financially fit penny stock shortlist

Mesoblast and the two other penny stocks in this article all came from a single screener, but the real edge is in building filters that match how you think about risk and reward. Use our flexible Screener to combine metrics like balance sheet strength, cash, valuation and growth potential, or jump straight into our curated Investing Ideas for ready made shortlists built around popular themes.

Clover Health Investments (CLOV)

Overview: Clover Health Investments runs a Medicare Advantage insurance business that offers PPO and HMO plans to Medicare eligible individuals, and also provides its Clover Assistant software to help physicians manage chronic diseases using data driven insights. The Medicare Advantage plans are the main revenue engine that links Clover Health to the Financially Fit Penny Stocks theme, with Clover Assistant acting as an additional, smaller technology enabled healthcare service.

Operations: Clover Health generates all of its US$2.5 billion in revenue from insurance operations in the United States, primarily through its Medicare Advantage segment.

Market Cap: US$2.3 billion

Investors looking at Clover Health Investments are really looking at a Medicare Advantage insurer that already generates meaningful revenue while trying to use technology to sharpen its margins. The combination of a data driven care model and the Clover Assistant software is intended to keep medical costs in check, which matters if the company is to move from recent losses to the profitability targets management is talking about for 2026 and beyond. At the same time, heavy reliance on Medicare Advantage reimbursement rules, higher risk external funding and recent insider selling mean you are not just buying a simple value story. Management is aiming to keep membership growing, hold down medical costs and convert better STAR ratings into stronger cash generation. The relationship between the current share price and analyst expectations is a key factor many market participants are watching.

Clover Health Investments is trying to turn heavy Medicare Advantage revenue into lasting profitability, and that tension between scale and execution risk is easy to miss in headlines. To see how the story looks when you pull together membership targets, cash generation ambitions and reimbursement exposure in one place, go straight to the analysis report for Clover Health Investments

Hyliion Holdings (HYLN)

Overview: Hyliion Holdings develops the KARNO Power Module, a fuel flexible power generator for stationary and mobile use that can run on conventional, waste and zero carbon fuels. This aligns directly with the Financially Fit Penny Stocks focus on early stage energy systems with practical, potentially lower cost power solutions. The company is still a specialist player rather than a broad utility, so your exposure is concentrated in this distributed power technology.

Operations: Hyliion Holdings currently generates about US$9 million in revenue from Auto Parts and Accessories in the United States.

Market Cap: US$730 million

Hyliion Holdings may be worth a closer look if you want targeted exposure to distributed power in a penny stock sized package. The KARNO Power Module is designed to give customers reliable on site generation that can run on fuels ranging from natural gas to landfill gas and renewable hydrogen, which fits with a screener focused on financially fitter early stage companies. Recent US Navy contracts, a growing pipeline of letters of intent and progress on additive manufacturing indicate potential for revenue growth if commercialization proceeds as planned. The risks are clear as well. Hyliion is still loss making, depends on external funding and faces execution risk if field trials, certification or supply chain plans are delayed.

Hyliion Holdings is trying to turn an early stage power module and recent US Navy interest into a real business, yet the full story on cash needs, contracts and execution risk only becomes clear in the analysis report for Hyliion Holdings

Seeking Fresh Alternatives Before They Fly

The next breakout candidates can move fast once momentum builds and attention catches up. Use these fresh stock shortlists while the data still matters and remains under the radar for now, then act based on your own analysis and timing.

• Identify cash-rich companies that still trade as if the market has not caught on yet by scanning the 14 high quality undervalued stocks before prices move away.
• Follow the shift toward automation while the theme builds by using the 37 robotics and automation stocks to find stocks connected to real-world robotics and factory upgrades.
• Explore the build out in computing power by using the 56 AI infrastructure stocks to find companies supplying the hardware and energy backbone for AI-related activity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.